Biosimilars
Biologics currently represent the majority of health care spending both for employers and patients in need of these treatments. This highlights the importance of focusing on the opportunity available in biosimilars — biologic medical products that have no meaningful clinical difference to their already approved reference drug. To reduce cost and increase access to life-saving treatments for patients, PBGH works with employers and purchasers to assess and break through barriers to adopting biosimilars.
Resources
Biosimilar Adoption: Challenges and Opportunities
Two Employer Plan Sponsors Biosimilar Savings Analysis
Biosimilars from the Physician Perspective
ACOs and Biosimilars
Past Events and Training
August 12, 2020
Biosimilars: The Next Frontier
The widespread use of biosimilars brings competition to the drug market and is estimated to save more than $54 billion over ten years.